It found that, of 107 responses, only 3% deemed that digital transformation would have no impact on the drug development timeline while ... driven drugs are in early stages suggests that more ...

Commissioner Markary announced the plans alongside the results of a generative AI pilot for scientific reviewers.

The healthcare and medical industries are increasingly integrating artificial intelligence into their operations, ...

The U.S. Centers for Medicare and Medicaid Services (CMS) said on Monday that it would announce a list of 15 drugs eligible ...

Janssen has ended the troubled phase 3 development programme for its fulranumab osteoarthritis pain drug, deciding that it was no longer a priority. The Johnson & Johnson (J&J) unit said yesterday ...

Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of ...